Table 3. Cox univariate and multivariate analyses.
| n (%) | HR | 95% CI | P-value | |
|---|---|---|---|---|
| (A) Whole-cohort clinicopathological variables (n=292), univariate analysis of breast cancer-specific death | ||||
| Age>50 | 184/292 (63) | 1.427 | 0.799–2.551 | 0.229 |
| Grade>2 | 132/291 (45) | 3.100 | 1.865–5.163 | <0.0001 |
| Size>20 mm | 117/291 (40) | 2.730 | 1.678–4.443 | <0.0001 |
| LN positive | 125/289 (43) | 3.968 | 2.346–6.774 | <0.0001 |
| HER-2 positive | 51/273 (18) | 2.459 | 1.463–4.134 | 0.0007 |
| ER positive | 192/280 (68) | 0.395 | 0.243–0.642 | 0.0002 |
| PR positive | 161/282 (57) | 0.238 | 0.140–0.406 | <0.0001 |
| BAG-1 high | 214/276 (78) | 0.364 | 0.222–0.598 | <0.0001 |
| (B) Whole-cohort (n=276) distant metastases, Cox multivariate analysis | ||||
| Grade>2 | 1.398 | 0.751–2.567 | 0.2948 | |
| Size>20 mm | 1.564 | 0.937–2.610 | 0.0873 | |
| LN status | 3.372 | 1.934–5.880 | <0.0001 | |
| HER-2 | 1.853 | 1.066–3.220 | 0.0287 | |
| ER | 0.990 | 0.525–1.868 | 0.9745 | |
| PR | 0.405 | 0.212–0.776 | 0.0064 | |
| BAG-1 high | 0.559 | 0.317–0.989 | 0.0455 | |
| (C) Whole-cohort distant metastases, Cox multivariate analysis, resolved model | ||||
| LN status | 3.597 | 2.097–6.168 | <0.0001 | |
| HER-2 | 1.973 | 1.158–3.361 | 0.0125 | |
| PR | 0.329 | 0.186–0.584 | 0.0001 | |
| BAG-1 high | 0.586 | 0.344–0.998 | 0.0493 | |
| (D) ER+ (n=189) breast cancer-specific death, Cox multivariate analysis | ||||
| Grade>2 | 1.529 | 0.600–3.896 | 0.3730 | |
| Size>20 mm | 1.053 | 0.428–2.591 | 0.9100 | |
| LN status | 1.471 | 0.571–3.795 | 0.4250 | |
| HER-2 | 5.578 | 2.036–15.286 | 0.0008 | |
| PR | 0.293 | 0.119–0.721 | 0.0076 | |
| BAG-1 high | 0.290 | 0.114–0.735 | 0.0090 | |
| (E) ER+ breast cancer-specific death, Cox multivariate analysis, resolved model | ||||
| HER-2 | 6.725 | 2.7–16.644 | <0.0001 | |
| PR | 0.239 | 0.104–0.547 | 0.0007 | |
| BAG-1 high | 0.302 | 0.122–0.744 | 0.0093 | |
CI=confidence interval; ER=oestrogen receptor; HR=hazards ratio.